IKTOS

Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery

Retrieved on: 
Tuesday, April 5, 2022
Software, Research, General Health, Pharmaceutical, Data Management, Technology, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, USD, Therapy, Rehabilitation, Neurology, CADD, Software as a service, Drug design, Research, Incorporated, CEO, B2B, Intelligence, Carbon, Solution, Quality of life, TSE, Software, JPY, Artificial intelligence, Technology, Safety, Time, Lists of diseases, Drug discovery, Efficiency, Analysis, B2C, AI, Deep learning, Patient, Nursing, Medical device, Pharmaceutical industry, Ikto!: 20 Megales Epitihies Tou, Teijin, IKTOS, THE TEIJIN GROUP

Under the agreement, Iktos generative modelling technology will be implemented and applied to several Teijin Pharmas small molecule drug discovery projects to expedite the identification of potential pre-clinical candidates.

Key Points: 
  • Under the agreement, Iktos generative modelling technology will be implemented and applied to several Teijin Pharmas small molecule drug discovery projects to expedite the identification of potential pre-clinical candidates.
  • Creating innovative drugs is one of the companys core business strategies and Teijin Pharma is now focusing on strengthening technological foundation for small molecule drugs that play major roles among the drug modalities for innovative drug discovery.
  • We are delighted to create innovative new small molecule drugs together with Iktos, said Ichiro Watanabe, President of Teijin Pharma.
  • Iktos proprietary AI technology will dramatically accelerate our small molecule drug discovery.

Iktos and Astrogen Announce a Research Collaboration to Use Artificial Intelligence Platform for Drug Design against a Novel Parkinson’s Disease Target

Retrieved on: 
Wednesday, January 5, 2022
Other Health, Software, Research, Data Management, Mental Health, Medical Devices, Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Time, Drug discovery, Autism spectrum, Intelligence, Analysis, AI, Artificial intelligence, Software, Astrogenes, Lists of diseases, Business, ASD, Parkinson's disease, Drug design, Software as a service, CEO, Business development, Technology, Solution, Deep learning, De novo, Pharmaceutical industry, Ikto!: 20 Megales Epitihies Tou, Iktos, Astrogen, IKTOS, ASTROGEN

Astrogen will contribute to in-vitro/in-vivo efficacy screening of lead compounds/pre-clinical drug candidates and will lead the entire development process from pre-clinical stage.

Key Points: 
  • Astrogen will contribute to in-vitro/in-vivo efficacy screening of lead compounds/pre-clinical drug candidates and will lead the entire development process from pre-clinical stage.
  • The companies will share responsibility for generating lead compounds and pursuing the optimal development path for selecting pre-clinical drug candidates.
  • We are proud and excited to announce our first collaboration deal in S. Korea bio-pharma sector commented Yann Gaston-Math, President and CEO of Iktos.
  • We are very pleased to collaborate with Iktos, one of the leading AI companies in drug design and discovery.

Iktos Announces Deployment of Their AI for Drug Design Software Makya™ by Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Retrieved on: 
Wednesday, December 8, 2021
Technology, Research, Medical Devices, Clinical Trials, Software, Biotechnology, Health, Pharmaceutical, Science, Cloud, Tao, Torreya, Jiangsu Hengrui Medicine, Analysis, Korea Carbon Capture & Sequestration R&D Center, Project Jupyter, Research, VPC, Technology, Pharma, Disease, Drug discovery, Artificial intelligence, Efficiency, CEO, Software, Deep learning, Virtual private cloud, Drug design, Intelligence, MPO, Solution, AI, Software as a service, De novo, Pharmaceutical industry, Fine chemical, Iktos, Jiangsu Hengrui Pharmaceuticals Co., Ltd., IKTOS, JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Under the agreement, Iktos de novo generative design software Makya will be used by Hengrui scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Hengrui Pharmas drug discovery programmes.

Key Points: 
  • Under the agreement, Iktos de novo generative design software Makya will be used by Hengrui scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Hengrui Pharmas drug discovery programmes.
  • This tackles one of the key challenges in drug design: rapid identification of molecules which simultaneously satisfy multiple bioactivity and drug-like criteria for drug discovery and development.
  • Innovation is the core development strategy, said Dr. Weikang Tao, Vice President of Hengrui Pharma and CEO of R&D Centers.
  • We are excited about the opportunity to use Iktos proprietary AI platform to beef up our drug design and discovery capability to better address unmet clinical needs.

Iktos Announces Collaboration with Kadmon to Use AI for New Drug Design

Retrieved on: 
Tuesday, May 18, 2021
Other Manufacturing, Technology, Medical devices, Chemicals, Plastics, Software, Manufacturing, Biotechnology, Pharmaceutical, Health, Data management, Health sciences, Pharmaceutical sciences, Life sciences, Medicinal chemistry, Drug discovery, Design of experiments, Drug design, Medication, Intel X99, Kadmon, Iktos, Kadmon, IKTOS, KADMON

b'Iktos, a company specializing in Artificial Intelligence for new drug design, today announced that it has entered into a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, pursuant to which, Iktos\xe2\x80\x99s generative modelling artificial intelligence (AI) technology will be used to enable the rapid and cost-effective design of novel drug candidates for an undisclosed Kadmon drug discovery program.

Key Points: 
  • b'Iktos, a company specializing in Artificial Intelligence for new drug design, today announced that it has entered into a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, pursuant to which, Iktos\xe2\x80\x99s generative modelling artificial intelligence (AI) technology will be used to enable the rapid and cost-effective design of novel drug candidates for an undisclosed Kadmon drug discovery program.
  • Kadmon is expanding and integrating novel drug discovery platforms, with the aim of identifying and developing new product candidates for significant unmet medical needs.
  • Iktos\xe2\x80\x99 technology automatically designs virtual novel molecules that have all of the characteristics of a successful drug molecule.
  • In early-stage discovery projects, Iktos\xe2\x80\x99 technology allows the design of novel hits with optimal protein-ligand interactions, as predicted by molecular modelling technology.

Iktos and Facio Therapies Announce Collaboration to Use AI for FSHD Drug Design

Retrieved on: 
Tuesday, May 11, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Technology, Other Technology, Other Health, Health sciences, Facioscapulohumeral muscular dystrophy, Muscular dystrophy, Evotec, Facio, Drug discovery, Health, Iktos, Facio Therapies, IKTOS, FACIO THERAPIES

b'Iktos, a company specialized in Artificial Intelligence for new drug design, and Facio Therapies, a drug discovery and development company focused on developing treatments for facioscapulohumeral dystrophy (FSHD), today announced entering a collaboration to apply Iktos\xe2\x80\x99s generative modelling artificial intelligence (AI) technology in one of Facio\xe2\x80\x99s drug discovery programs.

Key Points: 
  • b'Iktos, a company specialized in Artificial Intelligence for new drug design, and Facio Therapies, a drug discovery and development company focused on developing treatments for facioscapulohumeral dystrophy (FSHD), today announced entering a collaboration to apply Iktos\xe2\x80\x99s generative modelling artificial intelligence (AI) technology in one of Facio\xe2\x80\x99s drug discovery programs.
  • This technology automatically designs virtual novel molecules with all of the characteristics of a successful drug molecule.
  • Since inception, Facio has raised close to \xe2\x82\xac28M in equity funding from FSHD-affected families, their friends, FSHD foundations, and Facio\xe2\x80\x99s drug discovery partner, Evotec.
  • Facio has been founded by business leaders from the FSHD community \xe2\x80\x93 Kees van der Graaf (Netherlands), Neil Camarta (Canada), and Bill Moss (Australia).\n'